Business

The FDA has issued a drug shortage report for Foradil Aerolizer formoterol fumarate inhalation powder due to discontinuation of the product. According to the FDA website: "Novartis (manufacturer) and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer for business reasons. It is anticipated that inventory will be exhausted and no … [Read more...] about Foradil Aerolizer discontinued

Imprimis Pharmaceuticals has announced the acquisition of what it says are the largest compounding pharmacies for sinus drugs in the US: Topical Apothecary Group, LLC (doing business as TAG Pharmacy), Aerosol Science Laboratories, Inc. (ASL Pharmacy), and SinuTopic, Inc. (Sinus Dynamics Pharmacy). Websites for all three are nearly identical, offering compounding of … [Read more...] about Imprimis Pharmaceuticals acquires intranasal formulation compounding pharmacies

Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel's Precision Olfactory Delivery (POD) platform. Impel recently announced a partnership with 3M Drug Delivery Systems for development and commercialization of the intranasal technology. Impel CEO … [Read more...] about Impel NeuroPharma gets investment from 3M New Ventures

Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the product. Alexza announced in June 2015 that it would stop manufacturing Adasuve for its partners and in September said that it was considering … [Read more...] about Ferrer affirms commitment to Adasuve

Eli Lilly has acquired worldwide rights to Locemia Solution's intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed. Lilly Diabetes President Enrique … [Read more...] about Lilly acquires Locemia’s intranasal glucagon powder

OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products. The company had announced completion of its previous round of financing in August 2014. According to the company, Phase 3 development of … [Read more...] about OptiNose raises up to $30 million for development of intranasal fluticasone

InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company's inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary … [Read more...] about InCarda gets patents for inhaled cardiovascular therapies

Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the treatment of idiopathic pulmonary fibrosis, the companies said. A dry powder formulation of CM-YJH01, a biologic, will be developed using … [Read more...] about Celdara Medical and Pulmatrix get grant for inhaled biologic for idiopathic pulmonary fibrosis

GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies' PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in 2012. Liquidia also said that it has retained the right to develop an inhaled therapy independently. Upon … [Read more...] about GSK exercises option to develop inhaled drugs based on Liquidia’s PRINT technology